VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Firm”), an organization creating next-generation applied sciences in aesthetics and orthopedics, is happy to announce that it has closed the ultimate tranche of the funding by MainPointe Prescription drugs (“MainPointe”) as outlined within the share buy settlement signed by the events earlier this yr.
The ultimate tranche concerned the issuance of 1,479,882 frequent shares (the “Shares”) by RepliCel in trade for CAD$998,921 which has now been acquired by the Firm. The Firm acquired an combination of CAD$2,698,921 from all tranches and issued an combination of three,986,684 Shares at a value of CAD$0.675 per Share.
“The timing of this last share buy by MainPointe,” acknowledged RepliCel’s President and CEO, R. Lee Buckler, “coincides properly with the rising degree of collaboration between RepliCel, the European agency conducting the DermaPrecise growth, testing, and manufacturing (A.M.I.), and MainPointe’s regulatory division dedicated to dealing with all points of the regulatory submission to the U.S. Meals and Drug Administration in search of advertising approval for the injector and associated single-use consumables.”
All Shares issued are topic to a statutory maintain interval expiring 4 months and at some point from the date of the issuance of the Shares. Not one of the securities offered in reference to the funding shall be registered below the US Securities Act of 1933, as amended, and no such securities could also be provided or offered in the US absent registration or an relevant exemption from the registration necessities. This information launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase nor shall there be any sale of the securities in any jurisdiction wherein such supply, solicitation or sale can be illegal.
About RepliCel Life Sciences
RepliCel is a regenerative drugs firm targeted on creating cell therapies for aesthetic and orthopedic circumstances affecting what the Firm believes is roughly one in three folks in industrialized nations, together with getting older/sun-damaged pores and skin, sample baldness, and power tendon degeneration. These circumstances, usually related to getting older, are brought on by a deficit of wholesome cells required for regular tissue therapeutic and performance. These cell remedy product candidates are based mostly on RepliCel’s modern expertise, using cell populations remoted from a affected person’s wholesome hair follicles.
The Firm’s product pipeline is comprised of RCT-01 for tendon restore, RCS-01 for pores and skin rejuvenation, and RCH-01 for hair restoration. RCH-01 was solely licensed in Asia to Shiseido Firm (an settlement which is at the moment in dispute). RepliCel maintains the undisputed rights to RCH-01 for the remainder of the world. RCT-01 and RCS-01 are solely licensed in Better China to YOFOTO (China) Well being Firm. RepliCel and YOFOTO are at the moment co-developing these merchandise in China. RepliCel maintains the rights to those merchandise outdoors of Better China.
RepliCel has additionally developed a proprietary injection machine, RCI-02, and associated consumables, which is anticipated to enhance the administration of its cell remedy merchandise and sure different injectables. YOFOTO has solely licensed the business rights for the RCI-02 machine and consumables in Better China for dermatology purposes and is anticipated to first launch the product in Hong Kong upon it being accepted for market launch in both the US or Europe.
Please go to www.replicel.com for extra data.
RepliCel’s three cell remedy merchandise have now been examined in over 100 sufferers in 4 international locations on three continents having been efficiently reviewed by three regulatory businesses.RepliCel has key strategic companions in the US, China, and Japan every of which is now investing closely within the additional scientific testing and growth of RepliCel’s merchandise for his or her markets. Knowledge from every of the scientific applications will strengthen the product growth initiatives for RepliCel and its different companions worldwide.
For extra data, please contact:
Lee Buckler, CEO and President
Neither TSX Enterprise Alternate nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts duty for the adequacy or accuracy of this launch.
SOURCE: RepliCel Life Sciences, Inc.
View supply model on accesswire.com: